NYSE · Biotech stocks database
TAK — Takeda Pharmaceutical Company Limited ☆
TAK (Takeda Pharmaceutical Company Limited) stock: $21.01, $66.39B market cap, $2.58B cash, $92.39B EV, $66.38B fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Overview
Catalysts
Assets
Pipeline
Trials
Holders
News
What they do
Operating and Financial Review and Prospects” and elsewhere in this annual report. Identity of Directors, Senior Management and Advisers A. Directors and Senior Management Not applicable.
Source: 20-F FY2026 via SEC EDGAR
Enterprise value
$92,385.9M
Balance sheet
Cash $2,576.4M Debt $28,574.0M Net cash -$25,997.6M Enterprise value $92,385.9M Basic shares 3,159.7M shares Fully diluted shares 3,159.7M shares Fully diluted market cap $66,384.7M Cash per share $0.82
Cash figures as of 2025-03-31. Database snapshot: 2026-11-07.
Share structure
Cap table as of 2026-03-31.
Price history Loading TAK daily closes…
Loading price history…
Next catalyst TAK-861 · Nov 13 - Dec 25 in 6d · Phase 3 · Narcolepsy Type 1 (NT1); Narcolepsy With CataplexyAll upcoming catalysts (+66 more) →
Recently reported TAK-881 Phase 2/3 Positive · 2026-10-14
TAK-881-3001 · primary immunodeficiency diseases (pid)
Primary: Pharmacokinetic comparability of TAK-881 vs HYQVIA (IgG exposure) in participants aged 16 and older with primary immunodeficiency — Primary endpoint met (previously reported topline): PK comparability demonstrated; steady-state IgG trough geometric means 11.7 g/L on TAK-881 vs 11.9 g/L on HYQVIA, above protective thresholds
· Same immunoglobulin dose in 50% less infusion volume; median infusion time 75.8 vs 132 minutes (one site) and 58.3 vs 86 minutes (two sites)
· Annualized infection rates 2.62 on TAK-881 vs 2.73 on HYQVIA; annualized serious bacterial infection rate 0.0558 on TAK-881
· TEAEs 56.1% (23/41) on TAK-881 vs 50.0% (19/38) on HYQVIA; no TAK-881-related Grade 3+ TEAEs, serious AEs, or discontinuations due to related AEs
· Takeda plans regulatory submissions in the US, EU and Japan in fiscal 2026
Zasocitinib Phase 3 Positive · 2026-09-30
TAK-279
TAK-861 Phase 2 Positive · 2026-07-10
TAK-861 Phase 2 NT1 · narcolepsy type 1
Upcoming catalysts Expected Drug Phase Indication Mgmt guide Nov 13 - Dec 25 in 6d TAK-861 Phase 3 Narcolepsy Type 1 (NT1); Narcolepsy With Cataplexy — Dec 12, 2026 - Jan 23, 2027 in 5 wks TAK-788 Phase 3 Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) — Dec 12, 2026 - Jan 23, 2027 in 5 wks TAK-788 Phase 2 Carcinoma, Non-Small-Cell Lung — Jan 11 - Feb 22 in 9 wks TAK-360 Phase 2 Idiopathic Hypersomnia — Jan 11 - Feb 22 in 9 wks TAK-360 Phase 2 Narcolepsy Type 2 — Jan 12 - Feb 23 in 9 wks Lenalidomide Phase 2 Myeloma, Multiple — Jan 12 - Feb 23 in 9 wks DNL593 Phase 2 Frontotemporal Dementia — GUIDED Est. Feb 14, 2027 in 8 wks quarter midpoint
zasocitinib (TAK-279)moderate-to-severe plaque psoriasis, FDA NDA under priority review
Not disclosed moderate-to-severe plaque psoriasis, FDA under priority review Q1 2027 Feb 11 - Mar 25 in 14 wks Maribavir Phase 3 Cytomegalovirus (CMV) — Feb 12 - Mar 26 in 14 wks fruquintinib Phase 2 Colon Cancer; Rectal Cancer; Colorectal Cancer — Mar 1 - Apr 12 in 16 wks Maribavir Phase 3 Cytomegalovirus (CMV) — Mar 24 - May 5 in 5 mo Teduglutide Phase 3 Short Bowel Syndrome — Mar 31 - May 12 in 5 mo TAK-279 Phase 2 Crohn's Disease — Apr 27 - Jun 8 in 6 mo TAK-755 Phase 3 Thrombotic Thrombocytopenic Purpura (TTP) — May 26 - Jul 7 in 7 mo TDV Phase 3 Dengue Fever — Jun 29 - Aug 10 in 8 mo Zasocitinib Phase 3 Psoriatic Arthritis — Jun 29 - Aug 10 in 8 mo Zasocitinib Phase 3 Psoriatic Arthritis — Jul 11 - Aug 22 in 8 mo Zasocitinib Phase 3 Palmoplantar Psoriasis — Jul 20 - Aug 31 in 8 mo Vedolizumab Phase 3 Crohn's Disease — Sep 12 - Oct 24 in 10 mo ZED1227 Phase 2 Celiac Disease — Oct 25 - Dec 6 in 12 mo Vedolizumab IV Phase 3 Crohn's Disease (CD) — Nov 5 - Dec 17 in 12 mo Vedolizumab IV Phase 3 Moderately to Severely Active Ulcerative Colitis — Nov 23, 2027 - Jan 4, 2028 in 13 mo Zasocitinib Phase 2 Nonsegmental Vitiligo — Dec 9, 2027 - Jan 20, 2028 in 13 mo Rusfertide Phase 2 Polycythemia Vera — Jan 6 - Feb 17 in 14 mo VONVENDI Phase 3 Von Willebrand Disease (VWD) — Jan 9 - Feb 20 in 14 mo TAK-360 Phase 2 Narcolepsy Type 1 — Jan 13 - Feb 24 in 14 mo TAK-411 Phase 2 Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) — Jan 17 - Feb 28 in 15 mo TAK-755 Phase 2 Acute Ischemic Stroke — Apr 4 - May 16 in 17 mo Zasocitinib (Dose A) Phase 2 Hidradenitis Suppurativa — Apr 10 - May 22 in 17 mo TAK-861 Phase 3 Narcolepsy Type 1 — Apr 10 - May 22 in 17 mo Elritercept Phase 2 Myelofibrosis — Apr 27 - Jun 8 in 18 mo Mezagitamab Phase 3 Immune Thrombocytopenic Purpura (ITP) — May 11 - Jun 22 in 18 mo Zasocitinib Phase 2 Crohn's Disease — May 18 - Jun 29 in 19 mo TAK-781 Phase 1 Healthy Volunteers; Primary Sclerosing Cholangitis — Jun 12 - Jul 24 in 19 mo Elritercept Phase 3 Myelodysplastic Syndromes — Jun 27 - Aug 8 in 20 mo TAK-881 Phase 3 Primary Immunodeficiency Diseases (PID) — Jun 27 - Aug 8 in 20 mo Vedolizumab IV Phase 3 Ulcerative Colitis; Crohn's Disease — Aug 6 - Sep 17 in 21 mo TAK-881 Phase 3 Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) — Aug 7 - Sep 18 in 21 mo TAK-226 Phase 2 Myelodysplastic Syndromes — Aug 12 - Sep 23 in 21 mo Rusfertide Phase 2 Polycythemia Vera — Oct 7 - Nov 18 in 23 mo Fazirsiran Injection Phase 3 Alpha1-Antitrypsin Deficiency — Oct 11 - Nov 22 in 23 mo TAK-330 Phase 3 Coagulation Disorder — Oct 19 - Nov 30 in 24 mo Mezagitamab Phase 3 Kidney Disease — Oct 23 - Dec 4 in 24 mo IGI, 10% Phase 3 Multiple Myeloma; Secondary Immunodeficiency — Dec 13, 2028 - Jan 24, 2029 in 26 mo TAK-928 Phase 3 IO-resistant sqNSCLC — Feb 6 - Mar 20 in 27 mo TAK-188 Phase 2 Advanced or Metastatic Solid Tumors — Feb 12 - Mar 26 in 28 mo Idursulfase-IT Phase 3 Hunter Syndrome — Feb 26 - Apr 9 in 28 mo Mezagitamab Phase 2 Antibody-Mediated Rejection (AMR) — Feb 28 - Apr 11 in 28 mo Fazirsiran Injection Phase 3 Alpha1-Antitrypsin Deficiency — Jun 11 - Jul 23 in 32 mo Elritercept Phase 3 Myelodysplastic Syndrome; Anemia — Sep 9 - Oct 21 in 35 mo Mezagitamab Phase 3 Immune Thrombocytopenic Purpura (ITP) — Sep 16 - Oct 28 in 35 mo TAK-279 Phase 3 Plaque Psoriasis — Nov 11 - Dec 23 in 37 mo Vortioxetine tablets Phase 3 Major Depressive Disorder — Dec 11, 2029 - Jan 22, 2030 in 38 mo Elritercept Phase 2 Myelodysplastic Syndromes; Cytopenia — Jan 12 - Feb 23 in 39 mo Brigatinib Phase 2 Neurofibromatosis Type 2; Vestibular Schwannoma; Non-vestibular Schwannoma — Jan 18 - Mar 1 in 39 mo Elritercept Phase 3 Myelofibrosis; Anemia — Jan 29 - Mar 12 in 39 mo Zasocitinib Phase 3 Psoriatic Arthritis — Feb 10 - Mar 24 in 40 mo Zasocitinib Phase 2 Crohn's Disease; Ulcerative Colitis — Mar 14 - Apr 25 in 41 mo Vedolizumab Phase 3 Pouchitis — Apr 14 - May 26 in 42 mo TDV Phase 3 Dengue Fever — Apr 19 - May 31 in 42 mo Vedolizumab IV Phase 3 Crohn's Disease — May 23 - Jul 4 in 43 mo Vonicog Alfa Phase 3 Von Willebrand Disease (VWD) — Sep 23 - Nov 4 in 47 mo Vedolizumab SC Phase 3 Ulcerative Colitis; Crohn's Disease — Sep 29 - Nov 10 in 47 mo TAK-505 Phase 2 Malignant Solid Tumors — Jul 27 - Sep 7 in 57 mo TAK-360 Phase 3 Idiopathic Hypersomnia; Narcolepsy Type 1; Narcolepsy Type 2 — Mar 7 - Apr 18 in 77 mo Zasocitinib Phase 3 Plaque Psoriasis — Mar 21 - May 2 in 78 mo Vedolizumab IV Phase 3 Ulcerative Colitis; Crohn's Disease — Jun 13 - Jul 25 in 80 mo Fazirsiran Injection Phase 3 Alpha1-Antitrypsin Deficiency —
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Full readout calendar →
Pipeline assets zasocitinib
Phase 3 · Active Modality: small molecule (oral; allosteric TYK2 inhibitor)
Aliases TAK-279
Target TYK2
Partnerships Nimbus Therapeutics (acquired Feb 2023 via Nimbus Lakshmi)
Indications Plaque psoriasis (Phase 3) Inflammatory bowel disease (Stage not disclosed) Psoriatic arthritis (Stage not disclosed) Status note Positive Phase 3 results in psoriasis announced Dec 2025; on target for FDA NDA submission in calendar 2026.
rusfertide
Phase 3 · Active Modality: peptide (injectable hepcidin mimetic)
Target hepcidin
Partnerships Protagonist Therapeutics: worldwide license and collaboration (2024)
Indications Polycythemia vera (Phase 3) Status note Phase 3 VERIFY met primary and all key secondary endpoints (Mar 2025).
TAK-003
Approved · Active Modality: vaccine (dengue)
Status note Received positive EMA CHMP opinion; U.S. BLA voluntarily withdrawn Jul 2023 after FDA discussion on data collection.
soticlestat
Phase 3 · Terminated
Aliases TAK-935
Indications Dravet syndrome (Phase 3) Lennox-Gastaut syndrome (Phase 3) Status note Phase 3 SKYLINE and SKYWAY missed primary endpoints (Jun 2024); Takeda will not file for approval in either indication.
gamma delta T-cell therapy platform
Stage not disclosed · Terminated Modality: cell therapy
Status note Takeda discontinued its cell therapy efforts (Oct 2025); ~JPY 58.2B impairment on related intangible assets.
TAK-186
Stage not disclosed · Terminated
Partnerships Maverick Therapeutics (acquired)
Status note Development terminated (JPY 27.8B impairment with TAK-280).
TAK-280
Stage not disclosed · Terminated
Partnerships Maverick Therapeutics (acquired)
Status note Development terminated.
ALOFISEL
Approved · Terminated
Target Adipose-derived mesenchymal stem cells (darvadstrocel)
Indications Complex perianal fistulas in Crohn's disease (Approved) Status note EU marketing authorization voluntarily withdrawn Dec 2024 after ADMIRE-CD II missed primary endpoints; discontinued or phased out in markets outside the EU including Japan.
Per-asset detail extracted from the 20-F filed 2026-06-17. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
Active clinical trials Trial Phase Status Role Sponsor BP Condition(s) Mgmt guide NCT07363720 Phase 3 Active, not recruiting Sponsor TAK — Narcolepsy Type 1 (NT1); Narcolepsy With Cataplexy — NCT04129502 Phase 3 Active, not recruiting Sponsor TAK — Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) — NCT06439342 Phase 3 Recruiting Sponsor TAK — Cytomegalovirus (CMV) — NCT05319353 Phase 3 Recruiting Sponsor TAK — Cytomegalovirus (CMV) — NCT06973304 Phase 3 Active, not recruiting Sponsor TAK — Short Bowel Syndrome — NCT04683003 Phase 3 Active, not recruiting Sponsor TAK — Thrombotic Thrombocytopenic Purpura (TTP) — NCT06579755 Phase 3 Recruiting Sponsor TAK — Dengue Fever — NCT06671483 Phase 3 Recruiting Sponsor TAK — Psoriatic Arthritis — NCT06671496 Phase 3 Recruiting Sponsor TAK — Psoriatic Arthritis — NCT07752108 Phase 3 Not yet recruiting Sponsor TAK — Palmoplantar Psoriasis — NCT06227910 Phase 3 Recruiting Sponsor TAK — Crohn's Disease — NCT04779320 Phase 3 Recruiting Sponsor TAK — Crohn's Disease (CD) —
Sponsor-matched active trials from ClinicalTrials.gov (124 as sponsor, 60 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
View all 184 active trials for Takeda on ClinicalTrials.gov
Specialist fund holders Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Fully Diluted · Free biotech stocks database. Figures are sourced from SEC filings and company disclosures; not investment advice.